Treatment of Endometriosis by Nasal Administration of Nafarelin

Endometriosis, the ectopic location of endometrial tissue, may have an incidence up to 6% of all women of reproductive age. Patients present with symptoms ranging from chronic pelvic pain, to dyspareunia to infertility. Up to 50% of infertile women may have associated endometriosis. The condition ameliorates during pregnancy and spontaneously resolves at the menopause and after oophorectomy. There is however no uniformly successful therapy for endometriosis when future fertility is desired. Treatment has included conservative surgery, combination high dose oral contraceptives taken continuously for 6 months (induced pseudopregnancy) and more recently, danazol, an androgenic isoxazole derivative of 17α-ethinyl testosterone. While daily doses of 400–800 mg for 6 months of this steroid lead to clinical and objective improvement in up to 70% of cases, approximately 85% of patients experience troublesome side effects including weight gain, reduced breast size, acne and hirsutism [1–4]. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

Barbieri, R.L. and Ryan, K.G. Danazol: endocrine pharmacology and therapeutic application. Am. J. Obstet. Gynecol., 141, 453 (1981) Barbieri, R.L., Evans, S. and Kistner, R.W. Danazol in the treatment of endometriosis: analysis of 100 cases with a four year follow-up. Fertil. Steril., 37, 737 (1982) Biberoglu, K.O. and Behrman, S.J. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am. J. Obstet. Gynecol., 139, 645 (1981) Buttram, V.C., Jr., Belue, J.B. and Reiter, R. Interim report of a study of danazol for the treatment of endometriosis. Fertil. Steril., 37, 478 (1982) Meldrum, D.R., Chang, R.J., Lu, J., Vale, W., Rivier, J. and Judd, H.L. “Medical oophorectomy” using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. J. Clin. Endocrinol. Metab., 54, 1081 (1982) Meldrum, D.R., Pardridge, W.M., Karow, W.G., Rivier, J., Vale, W. and Judd, H.L. Hormonal effects of danazol and medical oophorectomy in endometriosis. Obstet. Gynecol., 62, 480 (1983) Shaw, R.W., Fraser, H.M. and Boyle, H. Intranasal treatment with luteinizing hormone-releasing hormone agonist in women with endometriosis. Brit. Med. J., 287, 1667 (1983) Lemay, A., Maheux, R., Faure, N., Jean, C. and Fazekas, A.T.A. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil. Steril., 41, 863 (1984) Pring, D.W., Maresh, M. and Fraser, A.C. Luteinizing hormone-releasing hormone agonist in women with endometriosis. Brit. Med. J., 287, 1718 (1983) Steingold, K.A., Lu, J.K., Randle, D., Moore, J.G., Judd, H.L. and Meldrum, D.R. Treatment of endometriosis with a long-acting GnRH analog a blinded evaluation. Proc. 32nd Ann. Meet. Soc. Gynec. Invest., Phoenix, Arizona (1985) Zorn, J.R., Tanger, Ch., Roger, M., Grenier, J., Comaru-Schally, A.M. and Schally, A.V. Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis. Int. J. Fert., 31, 11 (1986) Anonymous. LHRH analogues in endometriosis. Lancet, Nov. 1, 1016 (1986) McLachlan, R.I., Healy, D.L. and Burger, H.G. Clinical aspects of LHRH analogues in gynaecology: a review. Brit. J. Obstet. Gynaecol., 93, 431 (1986) Nillius, S.J., Bergquist, C. and Wide, L. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue. A new approach to birth control? Contraception, 17, 537 (1978) Gudmundsson, J.A., Nillius, S.J. and Bergquist, C. Inhibition of ovulation by intranasal nafarelin: a new super-active agonist of GnRH. Contraception, 30, 107 (1984) Brenner, P.F., Shoupe, D. and Mishell, D.R. Ovulation inhibition with nafarelin acetate administration for six months. Contraception, 32, 531 (1985) Monroe, S.E., Blumenfeld, Z., Andreyko, J.L., Shriock, E., Henzl, M.R. and Jaffe, R.B. Dose-dependent inhibition of pituitary-ovarian function during administration of a GnRH agonistic analog (nafarelin). J. Clin. Endocrinol. Metab., 63, 1334 (1986) Chiang, R-S., Barnes, R.B., Shoupe, D. and Lobo, R.A. Dose-related changes in LH bioactivity with intranasal GnRH agonist administration. Contraception, 32, 347 (1985) Meldrum, D.R., Tsao, Z., Monroe, S.E., Braunstein, G.D., Sladek, J., Lu, J.K.H., Vale, W., Rivier, J., Judd, H.L. and Chang, R.J. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J. Clin. Endocrinol. Metab., 58, 755 (1984) Shriock, E., Monroe, S.E., Henzl, M. and Jaffe, R.B. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil. Steril., 44, 583 (1985) Henzl, M.R., Monroe, S.E. Carson, S.L. and Moghissi, K. Management of endometriosis with nasal dosing of a GnRH agonist-nafarelin. Endocrinology, 118, 26A (1986) American Fertility Society: Classification of endometriosis. Fertil. Steril., 32, 633 (1979) Cann, C.E., Henzl, M., Burry, K., Andreyko, J., Hanson, F., Adamson, D. and Trobough, G. Reversible bone loss is induced by GnRH agonists. Endocrinology, 118, 24A (1986) Author information Authors and Affiliations Editor information Rights and permissions Copyright information © 1987 MTP Press Limited About this chapter Cite this chapter Henzl, M.R., Monroe, S.E. (1987). Treatment of Endometriosis by Nasal Administration of Nafarelin. In: Vickery, B.H., Nestor, J.J. (eds) LHRH and Its Analogs. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3229-6_22 Download citation DOI: https://doi.org/10.1007/978-94-009-3229-6_22 Publisher Name: Springer, Dordrecht Print ISBN: 978-94-010-7949-5 Online ISBN: 978-94-009-3229-6 eBook Packages: Springer Book Archive

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.